Cardiovascular disease and dyslipidemia: Beyond LDL

Current Pharmaceutical Design

Volumn 17, Issue 9, 2011, Pages 861-870

  Pöss, Janine ^a   Custodis, Florian ^a   Werner, Christian ^a   Weingärtner, Oliver ^a   Böhm, Michael ^a   Laufs, Ulrich ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

CETP; Dyslipidemia; HDL; LDL; Triglycerides

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL ESTER; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; RISK FACTORS;

EID: 79958228777     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795428858     Document Type: Article

References (86)

1. Stamler J, Wentworth D, Neaton JD. Is relationship between serumcholesterol and risk of premature death from coronary heart diseasecontinuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256(20): 2823-8
2. MRC/BHF Heart Protection Study of antioxidant vitaminsupplementation in 20[Punctuation space]536 high-risk individuals:a randomised placebo-controlled trial. The Lancet 20 2002;360 (9326): 23-33
3. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin oncoronary disease events in subgroups defined by coronary riskfactors: the Prospective Pravastatin Pooling Project. Circulation 2000; 102(16): 1893-900
4. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety ofcholesterol-lowering treatment: prospective meta-analysis of datafrom 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267-78
5. Pöss J, Böhm M, Laufs U. [Are the guidelines correct? Should allpatients with coronary heart disease or diabetes be treated with astatin?]. Med Klin (Munich) 2009; 104(1): 74-8
6. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety ofmore intensive lowering of LDL cholesterol: a meta-analysis ofdata from 170,000 participants in 26 randomised trials. Lancet. Nov13; 376(9753): 1670-81
7. Third Report of the National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, and Treatment ofHigh Blood Cholesterol in Adults (Adult Treatment Panel III) finalreport. Circulation 2002; 106(25): 3143-421
8. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronaryheart disease. The Framingham Study. Am J Med 1977; 62(5): 707-14
9. Assmann G, Schulte H. The Prospective Cardiovascular Munster(PROCAM) study: prevalence of hyperlipidemia in persons withhypertension and/or diabetes mellitus and the relationship tocoronary heart disease. Am Heart J 1988; 116(6 Pt 2): 1713-24
10. Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: StatinTherapy Does Not Alter the Association Between Low Levels ofHigh-Density Lipoprotein Cholesterol and IncreasedCardiovascular Risk. Ann Intern Med.; 153(12): 800-8
11. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines oncardiovascular disease prevention in clinical practice: executivesummary. Eur Heart J 2007; 28(19): 2375-414
12. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association betweenchange in high density lipoprotein cholesterol and cardiovasculardisease morbidity and mortality: systematic review and metaregressionanalysis. BMJ 2009; 338: b92
13. Pöss J, Böhm M, Laufs U. [HDL and CETP in atherogenesis].Dtsch Med Wochenschr. Feb; 135(5): 188-92
14. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008; 23(4): 370-8
15. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004; 95(8): 764-72
16. Negre-Salvayre A, Dousset N, Ferretti G, Bacchetti T, Curatola G, Salvayre R. Antioxidant and cytoprotective properties of highdensitylipoproteins in vascular cells. Free Radic Biol Med 2006;41(7): 1031-40
17. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial andantithrombotic actions of HDL. Circ Res 2006; 98(11): 1352-64
18. Fogelman AM. When good cholesterol goes bad. Nat Med 2004;10(9): 902-3
19. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: proatherogenic HDL--an evolving field. Nat Clin Pract Endocrinol Metab 2006; 2(9):504-11
20. Navab M, Ananthramaiah GM, Reddy ST, et al. The doublejeopardy of HDL. Ann Med 2005; 37(3): 173-8
21. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that isdysfunctional in preventing the formation of or inactivatingoxidized phospholipids. J Lipid Res 2001; 42(8): 1308-17
22. Hedrick CC, Thorpe SR, Fu MX, et al. Glycation impairs highdensitylipoprotein function. Diabetologia 2000; 43(3): 312-20
23. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascularstatus of carriers of the apolipoprotein A-I(Milano) mutant: theLimone sul Garda study. Circulation 2001; 103(15): 1949-54
24. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib inpatients at high risk for coronary events. N Engl J Med 2007;357(21): 2109-22
25. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterolefflux capacity, high-density lipoprotein function, andatherosclerosis. N Engl J Med.; 364(2): 127-35
26. Laufs U. [Stable coronary artery disease -- diagnosis and therapy].Dtsch Med Wochenschr 2006; 131(11): 556-62; quiz 63-4
27. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein asa therapeutic target: a systematic review. JAMA 2007; 298(7): 786-98
28. Meyers CD, Kashyap ML. Pharmacologic elevation of high-densitylipoproteins: recent insights on mechanism of action andatherosclerosis protection. Curr Opin Cardiol 2004; 19(4): 366-73
29. Jones PH, Davidson MH, Stein EA, et al. Comparison of theefficacy and safety of rosuvastatin versus atorvastatin, simvastatin,and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92(2): 152-60
30. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primarypreventiontrial with gemfibrozil in middle-aged men withdyslipidemia. Safety of treatment, changes in risk factors, andincidence of coronary heart disease. N Engl J Med 1987; 317(20):1237-45
31. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for thesecondary prevention of coronary heart disease in men with lowlevels of high-density lipoprotein cholesterol. Veterans AffairsHigh-Density Lipoprotein Cholesterol Intervention Trial StudyGroup. N Engl J Med 1999; 341(6): 410-8
32. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibroziltreatment and lipid levels with major coronary events: VA-HIT: arandomized controlled trial. JAMA 2001; 285(12): 1585-91
33. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibratetherapy on cardiovascular events in 9795 people with type 2diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366(9500): 1849-61
34. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combinationlipid therapy in type 2 diabetes mellitus. N Engl J Med.; 362(17):1563-74
35. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recentclinical trials for the National Cholesterol Education Program AdultTreatment Panel III Guidelines. J Am Coll Cardiol 2004; 44(3):720-32
36. Duffy D, Rader DJ. Update on strategies to increase HDL quantityand function. Nat Rev Cardiol 2009 Jul; 6(7): 455-63
37. Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile ofextended-release niacin/laropiprant versus gradually titrated niacinextended-release in patients with dyslipidemia with and withoutischemic cardiovascular disease. Am J Cardiol 2009; 104(1): 74-81
38. Clofibrate and niacin in coronary heart disease. JAMA 1975 Jan27; 231(4): 360-81
39. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality inCoronary Drug Project patients: long-term benefit with niacin. JAm Coll Cardiol 1986; 8(6): 1245-55
40. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. ArterialBiology for the Investigation of the Treatment Effects of ReducingCholesterol (ARBITER) 2: a double-blind, placebo-controlledstudy of extended-release niacin on atherosclerosis progression insecondary prevention patients treated with statins. Circulation 2004; 110(23): 3512-7
41. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin orezetimibe and carotid intima-media thickness. N Engl J Med 2009;361(22): 2113-22
42. Hirano K, Yamashita S, Nakajima N, et al. Genetic cholesterylester transfer protein deficiency is extremely frequent in theOmagari area of Japan. Marked hyperalphalipoproteinemia causedby CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 1997; 17(6): 1053-9
43. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heartdisease in Japanese-American men with mutation in the cholesterylester transfer protein gene despite increased HDL levels. J ClinInvest 1996; 97(12): 2917-23
44. Ritsch A, Scharnagl H, Eller P, et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation. Jan 26; 121(3): 366-74.
45. Curb JD, Abbott RD, Rodriguez BL, et al. A prospective study ofHDL-C and cholesteryl ester transfer protein gene mutations andthe risk of coronary heart disease in the elderly. J Lipid Res 2004;45(5): 948-53
46. Thompson A, Di Angelantonio E, Sarwar N, et al. Association ofcholesteryl ester transfer protein genotypes with CETP mass andactivity, lipid levels, and coronary risk. JAMA 2008; 299(23):2777-88
47. Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in ApoE and LDL receptorgene knock-out mice as a result of human cholesteryl ester transferprotein transgene expression. Arterioscler Thromb Vasc Biol 1999;19(4): 1105-10
48. Hayek T, Masucci-Magoulas L, Jiang X, et al. Decreased earlyatherosclerotic lesions in hypertriglyceridemic mice expressingcholesteryl ester transfer protein transgene. J Clin Invest 1995;96(4): 2071-4
49. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuatesatherosclerosis in rabbits. Nature 2000; 406(6792): 203-7
50. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of aninhibitor of cholesteryl ester transfer protein on HDL cholesterol. NEngl J Med 2004; 350(15): 1505-15
51. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on theprogression of coronary atherosclerosis. N Engl J Med 2007;356(13): 1304-16
52. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapibon carotid atherosclerosis in familial hypercholesterolemia. N EnglJ Med 2007; 356(16): 1620-30
53. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotidintima-media thickness in mixed dyslipidaemia (RADIANCE 2study): a randomised, double-blind trial. Lancet 2007; 370(9582):153-60
54. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-inducedblood pressure elevation is independent of CETP inhibition and isaccompanied by increased circulating levels of aldosterone. Br JPharmacol 2008; 154(7): 1465-73
55. Stein EA, Stroes ES, Steiner G, et al. Safety and tolerability ofdalcetrapib. Am J Cardiol 2009; 104(1): 82-91
56. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety ofthe cholesteryl ester transfer protein inhibitor anacetrapib asmonotherapy and coadministered with atorvastatin in dyslipidemicpatients. Am Heart J 2009; 157(2): 352-60+e2
57. Krishna R, Anderson MS, Bergman AJ, et al. Effect of thecholesteryl ester transfer protein inhibitor, anacetrapib, onlipoproteins in patients with dyslipidaemia and on 24-h ambulatoryblood pressure in healthy individuals: two double-blind,randomised placebo-controlled phase I studies. Lancet 2007;370(9603): 1907-14
58. Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale anddesign of the dal-OUTCOMES trial: efficacy and safety ofdalcetrapib in patients with recent acute coronary syndrome. AmHeart J 2009; 158(6): 896-901+e3
59. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib inpatients with or at high risk for coronary heart disease. N Engl JMed. Dec 16; 363(25): 2406-15
60. http://clinicaltrials.gov/ct2/show/NCT01252953?term=cetp+inhibi tion&rank=3
61. Ranalletta M, Bierilo KK, Chen Y, et al. Biochemicalcharacterization of cholesteryl ester transfer protein inhibitors. JLipid Res. Sep; 51(9): 2739-52
62. Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl estertransfer protein activity maintains efficient pre-beta-HDLformation and increases reverse cholesterol transport. J Lipid Res. Dec; 51(12): 3443-54
63. Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol effluxpotential and antiinflammatory properties of high-density lipoproteinafter treatment with niacin or anacetrapib. Arterioscler ThrombVasc Biol. Jul; 30(7): 1430-8
64. Yvan-Charvet L, Matsuura F, Wang N, et al. Inhibition ofcholesteryl ester transfer protein by torcetrapib modestly increasesmacrophage cholesterol efflux to HDL. Arterioscler Thromb VascBiol 2007; 27(5): 1132-8
65. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinantApoA-I Milano on coronary atherosclerosis in patients with acutecoronary syndromes: a randomized controlled trial. JAMA 2003;290(17): 2292-300
66. Austin MA. Plasma triglyceride and coronary heart disease.Arterioscler Thromb 1991; 11(1): 2-14
67. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factorfor cardiovascular disease independent of high-density lipoproteincholesterol level: a meta-analysis of population-based prospectivestudies. J Cardiovasc Risk 1996; 3(2): 213-9
68. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemiaand elevated lipoprotein(a) are risk factors for major coronaryevents in middle-aged men. Am J Cardiol 1996; 77(14): 1179-84
69. Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med 2007 Sep 6; 357(10): 1009-17
70. Tirosh A, Rudich A, Shochat T, et al. Changes in triglyceridelevels and risk for coronary heart disease in young men. Ann InternMed 2007; 147(6): 377-85
71. Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride-mediatedpathways and coronary disease: collaborative analysis of 101studies. Lancet. May 8; 375(9726): 1634-9
72. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk ofcardiovascular events in women. JAMA 2007; 298(3): 309-16
73. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemicheart disease, and death in men and women. JAMA 2007; 298(3):299-308
74. Eberly LE, Stamler J, Neaton JD. Relation of triglyceride levels,fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003; 163(9): 1077-83
75. Patsch JR, Miesenbock G, Hopferwieser T, et al. Relation oftriglyceride metabolism and coronary artery disease. Studies in thepostprandial state. Arterioscler Thromb 1992; 12(11): 1336-45
76. Ryu JE, Howard G, Craven TE, Bond MG, Hagaman AP, Crouse JR, 3rd. Postprandial triglyceridemia and carotid atherosclerosis inmiddle-aged subjects. Stroke 1992 Jun; 23(6): 823-8
77. Mohanlal N, Holman RR. A standardized triglyceride andcarbohydrate challenge: the oral triglyceride tolerance test. Diabetes Care 2004; 27(1): 89-94
78. Umpaichitra V, Banerji MA, Castells S. Postprandial hyperlipidemiaafter a fat loading test in minority adolescents with type 2diabetes mellitus and obesity. J Pediatr Endocrinol Metab 2004 Jun; 17(6): 853-64
79. Brunzell JD, Schrott HG, Motulsky AG, Bierman EL. Myocardialinfarction in the familial forms of hypertriglyceridemia. Metabolism 1976; 25(3): 313-20
80. Austin MA, McKnight B, Edwards KL, et al. Cardiovasculardisease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation 2000; 101(24): 2777-82
81. Mahley RW, Huang Y, Rall SC, Jr. Pathogenesis of type IIIhyperlipoproteinemia (dysbetalipoproteinemia). Questions,quandaries, and paradoxes. J Lipid Res 1999; 40(11): 1933-49
82. Zambon A, Brown BG, Deeb SS, Brunzell JD. Genetics ofapolipoprotein B and apolipoprotein AI and premature coronaryartery disease. J Intern Med 2006 May; 259(5): 473-80
83. Haffner SM. Dyslipidemia management in adults with diabetes.Diabetes Care 2004; 27 Suppl 1: S68-71
84. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin,antioxidant vitamins, or the combination for the prevention ofcoronary disease. N Engl J Med 2001; 345(22): 1583-92.
85. Davidson MH. Mechanisms for the hypotriglyceridemic effect ofmarine omega-3 fatty acids. Am J Cardiol 2006; 98(4A): 27i-33i
86. Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovasculareffects of marine omega-3 fatty acids. Lancet. Aug 14;376(9740): 540-50.